In previous studies in other cancer models, auraptene has been shown to inhibit ODC [13,20], induce Phase-II enzymes including glutathione-S-transferase (GST) and quinone reductase (QR) [6], and suppress matrix metalloproteinases (MMPs) [19]. The gene discussed is NQO1; the disease is cancer.